Study study type PathologyT1T0Patientssample sizesROB Results

mEC - (neo)adjuvant (NA) metastatic/advanced - esophageal cancer (mEC) mEC - (neo)adjuvant (NA)

versus placebo
nivolumab alone
CheckMate 577, 2021
  NCT02743494
RCTmEC - (neo)adjuvant (NA)nivolumabplaceboas adjuvant therapy in patientswith locally advanced (Adults with resected (R0)stage II or III) esophageal or gastroesophageal junction cancer with predominant adenocarcinomaor squamous-cell carcinoma.532 / 262some concern
conclusif
  • demonstrated 37 % decrease in events or deaths (EFS) (PE)

mEC - 1st line (L1) metastatic/advanced - esophageal cancer (mEC) mEC - 1st line (L1)

versus placebo plus SoC
pembrolizumab plus SoC
KEYNOTE-590 unpublished
  NCT03189719
RCTmEC - 1st line (L1)Pembrolizumab with cisplatin and 5 FU :placebo with cisplatin and 5 FU :as first-line treatment in Subjects With Advanced/Metastatic Esophageal squamous Carcinoma or EGJ373 / 376NA
conclusif
  • demonstrated 27 % decrease in deaths (OS) (PE)
  • demonstrated 35 % decrease in progression or deaths (PFS) (PE)
  • demonstrated 98 % increase in objective responses (ORR) (PE)
Pembrolizumab (Keytruda) in combination with chemotherapy significantly improved overallsurvival (OS) and progressionfree survival (PFS) in the frontline treatment of patients with locally advanced or metastatic esophageal cancer, meeting the primary end points of the phase 3 KEYNOTE-590 trial

mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)

versus Standard of Care (SoC)
camrelizumab alone
ESCORT, 2020
  NCT03099382
RCTmEC - 2nd line (L2)camrelizumabdocetaxel or irinotecanpatients aged 18 to 75 years with a histological or cytological diagnosis of advanced or metastatic oesophageal squamous cell carcinoma, had progressed on, or were intolerant to, first-line standard therapy.228 / 220high
conclusif
  • demonstrated 29 % decrease in deaths (OS) (PE)
  • suggested 31 % decrease in progression or deaths (PFS)
nivolumab alone
ATTRACTION-3, 2019
  NCT02569242
RCTmEC - 2nd line (L2)NivolumabICC Docetaxel/PaclitaxelPatients With Unresectable Advanced or Recurrent (squamous or adenosquamous) Esophageal (including the oesophagogastric junction) Cancer who have failed in standard chemotherapies.210 / 209high
conclusif
  • demonstrated 23 % decrease in deaths (OS) (PE)
  • statistically significant 64 % decrease in DCR
pembrolizumab alone
KEYNOTE-181, 2020
  NCT02564263
RCTmEC - 2nd line (L2)Pembrolizumabchemotherapy ICC (paclitaxel, docetaxel, or irinotecan)Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus/ or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) That Have Progressed After First-Line Standard Therapy314 / 314NA
inconclusive
  • inconclusive 11 % decrease in deaths (OS) (PE)
(Pembrolizumab significantly improved OS compared with chemo as second-line therapy for advanced esophageal cancer with PD-L1 CPS ≥10) => no stat plan